We know that Paclitaxel is insoluble in water,so the traditional Paclitaxel Injection uses castor oil to dissolve Paclitaxel,which brings several problems:
1.The drugs are not targeted at tumors.A large number of drugs have affected the whole body of patients.All parts and organs of the body are suffering from toxic damage.The side effects of chemotherapy with drugs are relatively strong;
2.Due to the toxicity and side effects on the whole body,the dosage of drugs is limited,which leads to some patients being no longer effective after a period of treatment and losing the follow-up treatment plan;
3.Castor oil is easy to cause allergy,so before each chemo,the patient needs to be pretreated with a variety of drugs to prevent allergy.
As Paclitaxel is still the most effective,broad-spectrum anti-cancer drug in the world,it is an inevitable trend for newer and better dosage forms to gradually replace the original dosage forms.
According to the analysis of clinical data and market sales trend,the two most potential dosage forms are as below:
1.Paclitaxel(Albumin-Bound for Injection)
2.Paclitaxel Polymeric Micelles for Injection
Here let’s take a look at the advantages of these 2 dosage forms.
As we see in the table,these two new dosage forms have obvious clinical advantages,so they have excellent performance after being marketed,even rapidly replacing the original traditional Paclitaxel Injection market.
Paclitaxel(Albumin-Bound for Injection)
Due to its advantages of good efficacy,convenient use and high safety,Paclitaxel(Albumin-Bound for Injection)has quickly replaced the market share of traditional paclitaxel injection,and widely used in multiple tumor indications after being included in the national medical insurance list.
Albumin paclitaxel was originally developed as BMS’s Abraxane,and its sales volume was 0.9 billion USD in 2021
In 2021,the sales of Paclitaxel(Albumin-Bound for Injection)at the end of public medical institutions in China approached 4 billion yuan(572 Million USD),with a growth of more than 10%in the first half of 2022.(population of China:1.4billion)
Paclitaxel(Albumin-Bound for Injection)is becoming the most popular fomulation of Paclitaxel.It is widely accepted by patients,doctors and governments because of its advantages and affordable price.
Paclitaxel Polymeric Micelles Injection
Paclitaxel Polymeric Micelles Injection is an improved new drug developed independently,which is not anda,and has no competitors currently.
Compared with albumin paclitaxel,it has better efficacy,safety,drug tolerance and other indicators,clinical promotion advantages,and large profit space.Therefore,it has just been approved for sales for half a year,and reached a net profit of 60 million yuan.
Till now this is the only approved Paclitaxel Polymeric Micelles Injection in worldwide,but a few pharmaceutical companies are in the process of R&D and clinical trials in different countries.
Albumin and micelles are perfect carriers of small molecule insoluble drugs.After Paclitaxel,they can also be used in Docetaxel,Cabazitaxel and other insoluble drugs.The market value brought by this technology is very considerable.
Hande Bio-Tech provides the whole package of technical transfer of these 2 dosage forms,to support your valuable project obtaining approval for commercial much quicker than others.
Contact us to know more,the chance can be yours.
Post time: Nov-29-2022